ValiRx PLC - Nuneaton, England-based drug development company - Widens pretax loss in 2021 to £1.7 million from £1.5 million the previous year. Research and development costs rise 32% to £303,789 in the year from £230,115 a year prior. Total assets at December 31 fall to £3.5 million from £4.9 million at the end of 2020. Chief Executive Suzanne Dilly says the work completed during 2021 has provided a ‘strong foundation’ for the company moving forward.

Current stock price: 24.20 pence

12-month change: up 26%

Copyright 2022 Alliance News Limited. All Rights Reserved.